Breast Cancer Survival Rate of Luminal vs Non-Luminal Subtype at Prof. Dr. Margono Soekarjo Regional General Hospital Purwokerto in 2021-2023
Keywords:breast cancer, luminal subtype, non luminal subtype, survival rate
Introduction: Breast cancer is a malignancy that originates from breast tissue such as epithelium, ducts and breast lobules. Breast cancer often occurs at a young age, due to many risk factors including alcohol consumption, diet, radiation and family history. Based on receptor gene expression in tissues, breast cancer is classified into two, namely luminal subtypes in the form of Luminal A and Luminal B, and non luminal subtypes in the form of Positive Human Epidermal Growth Factor Receptor 2 and Triple Negative Breast Cancer (TNBC). The survival rate for each subtype has a different time, so further understanding is needed to determine the right treatment for patients. This study aims to determine the relationship between survival rate and luminal and non luminal breast cancer subtypes. Methods: This study uses secondary data, namely the medical records of breast cancer patients at Prof. Hospital. Dr. Margono Soekarjo Purwokerto. The sample in this study were breast cancer patients at RSMS for the 2021-2023 period who fit the inclusion and exclusion criteria. Results: Of the 84 samples that complied, the survival rate for patients with the luminal subtype was 52.9%, while the survival rate for the non luminal subtype was 42.4%. Conclusion: The survival rate of breast cancer patients with luminal subtype is higher than that of non luminal breast cancer patients, and there is a relationship between survival rate with luminal and non luminal subtypes.
Suryani, Y. 2020. Kanker Payudara. Padang : PT. Freeline Cipta Granesia.
Susmini, Supriyadi. 2020. Hubungan Tingkat Pengetahuan dengan Kemampuan Pemeriksaan Dada Sendiri (Sadari) pada Wanita Usia Subur di Desa Sukodadi Kecamatan Wagir Kabupaten Malang. Jurnal Kesehatan Mesencephalon. Vol. 6(2) : pp. 101-106.
World Health Organization. 2020. Indonesia Source GLOBOCAN 2018, International Agency for Research on Cancer.
Yang, H. et al. 2020. Impact of Molecular Subtypes on Metastatic Behavior and Overall Survival in Patients with Metastatic Breast Cancer: A Single Center Study Combined with a Large Cohort Study Based on The Surveillance, Epidemiology and End Results Database. Oncology Letters, 20(4), pp. 1-11.
Brunicardi FC, Anderson DK, Billiar TR, Dunn DL, Hunter JG, Matthews JB et al. 2010. Schwartz’s Principles of Surgery. 9th edition. The united states of America: The McGraw Hill Companies, Inc.
Bacchi L.M, Corpa M, Santos P.P, Bacchi C.E, Carvalho F.M. 2018. Estrogen receptor-positive breast carcinomas in younger women are different from those of older women: a Pathological And Immunohistochemical Study. The Breast Elsevier, 19(2), pp. 137–41.
National Cancer Institute. 2020. Dictionary of Cancer Terms. https://www.cancer.gov/publications/dictionaries/cancerterms/def/overallsurvival. Diakses pada tanggal 15 April 2022.
Neve, RM. Chin, K. Fridlyand, J. Yeh, J. Baehner, FL. Fevr, T. Clark, L. Bayani, N. Coppe, J. Tong, F. Speed, T. Spellman, PT. DeVries, S. Lapuk, A. Wang, NJ. Kuo, W. Stilwell, JL. Pinkel, D. Albertson, DG. Waldman, FM. McCormick, F. Dickson, RB. Johnson, MD. Lippman, M. Ethier, S. Gazdar, A. Gray, JW. 2009. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 10(6), pp. 515-527.
Pellegrino, B. Hlavata, Z. Migali, C. el al. 2021. Luminal breast cancer: risk of recurrence and tumor-associated immune suppression.Mol Diagn Ther. 25(4): pp. 409-424.
Yersal, O. Barutca, S. 2014. Biological subtypes of breast cancer: Prognostic and therapeutic implications. World J Clin Oncol. 5(3): pp. 414–424.
Wiguna, NIP. Manuaba, IBTW. 2014. Karakteristik pemeriksaan imunohistokimia pada pasien kanker payudara di RSUP sanglah periode 2003-2021. Medika Udayana. 3(7): pp. 1-13.
Cho, N. 2016. Molecular subtypes and imaging phenotypes of breast cancer. Ultrasonography. 35(4): pp. 281-288.
How to Cite
Copyright (c) 2023 Muhammad Yamsun, Rafika Zamri
This work is licensed under a Creative Commons Attribution 4.0 International License.